– KVD900 Phase 1 Data Show Rapid Suppression of Plasma Kallikrein
Activity and is Well Tolerated for Potential Use as On-Demand Treatment
for HAE –
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--May 28, 2019--
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, announced data
that was presented at the C1 Inhibitor Deficiency and Angioedema
Workshop in Budapest, Hungary.
“KVD900 is an oral, novel, potent and selective inhibitor of plasma
kallikrein, a validated target in hereditary angioedema, or HAE,” said
Andrew Crockett, Chief Executive Officer of KalVista. “We believe KVD900
represents a new therapeutic opportunity to rapidly halt HAE attacks at
their earliest sign and we look forward to seeing the Phase 2 data late
KalVista’s oral presentation and poster showed:
KVD900 rapidly reached high levels of drug exposure and was well
tolerated without related gastrointestinal adverse events
KVD900 successfully interrupts the contact activation system’s
positive feedback loop between plasma kallikrein, prekallikrein, and
Within 10 minutes an inhibitory effect on plasma kallikrein activity
was detected with KVD900 in undiluted plasma and within 20 minutes it
was by greater than 95%. KVD900 provided critical high molecular
weight kininogen (HK) cleavage protection for at least 10 hours
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on
the discovery, development, and commercialization of small molecule
protease inhibitors for diseases with significant unmet need. The
initial focus is on inhibitors of plasma kallikrein, which is an
important component of the body’s inflammatory response and which, in
excess, can lead to increased vascular permeability, edema and
inflammation. KalVista has developed a proprietary portfolio of novel,
small molecule plasma kallikrein inhibitors initially targeting
hereditary angioedema (HAE) and diabetic macular edema (DME). The
Company has created a structurally diverse portfolio of oral plasma
kallikrein inhibitors and is advancing multiple drug candidates for HAE
as well as DME. The Company has selected KVD900 as its program to be
advanced as an on-demand therapy for HAE attacks and commenced a Phase 2
proof-of-concept study in HAE patients in late 2018. In DME, KalVista’s
most advanced program, an intravitreally administered plasma kallikrein
inhibitor known as KVD001, began a Phase 2 clinical trial in 2017 that
is anticipated to complete in the second half of 2019.
For more information, please visit www.kalvista.com.
This press release contains "forward-looking" statements within the
meaning of the safe harbor provisions of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as: "anticipate," "intend," "plan," "goal,"
"seek," "believe," "project," "estimate," "expect," "strategy,"
"future," "likely," "may," "should," "will" and similar references to
future periods. These statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially from
what we expect. Examples of forward-looking statements include, among
others, available funding, our cash runway and future clinical trial
timing and results. Further information on potential risk factors that
could affect our business and its financial results are detailed in the
annual report on Form 10-K filed on July 30, 2018 and other reports as
filed from time to time with the Securities and Exchange Commission. We
undertake no obligation to publicly update any forward-looking
statement, whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190528005185/en/
Source: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc.
Director, Corporate Communications & Investor Relations